Perindopril-erbumine-struc-form (Perindopril Erbumine Tablets 1)
Perindopril Erbumine
Product Images NDC 0527-1920
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Perindopril Erbumine (NDC 0527-1920). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Lannett Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Fig1 (Perindopril Erbumine Tablets 2)
The image shows a graph of time-to-event analysis comparing the efficacy of a placebo versus a medication called Perindopril in preventing cardiovascular mortality, nonfatal myocardial infarction or cardiac arrest. The primary endpoint favors the use of Perindopril with a statistically significant difference (Logrank p=0.0003). The x-axis represents the time in years, and the y-axis represents the proportion of patients who had an event. The number of patients at risk is also included at different time points.*
Fig2 (Perindopril Erbumine Tablets 3)
The text describes a figure showing the beneficial effect of Perindopril treatment on the primary endpoint in different subgroups such as male and female patients, age groups, patients with or without previous medical history, and those taking medication for hypertension, diabetes or lipid-lowering. The figure also shows the percentage of primary events and the number of patients in each group, represented by the size of the squares. The results suggest that Perindopril treatment is more effective than a placebo in reducing the primary endpoint.*
4mg-container-label (Perindopril Erbumine Tablets 4)
This is a description of Perindopril Erbumine tablets. Each tablet contains 4mg of perindopril erbumine. The dosage and administration information should be found on accompanying literature. The tablets should be stored at a controlled room temperature of 20 to 25°C and protected from moisture. They are manufactured by Patheon Pharmaceuticals, Inc. and marketed by Lannett. These tablets are a product of France and are sold in a bottle containing 100 tablets. Finally, it is advised to keep the tablets out of reach of children.*
8mg-container-label (Perindopril Erbumine Tablets 5)
Perindopril Erbumine Tablets, each containing 8 mg, are manufactured by Patheon Pharmaceuticals, Inc. and marketed by Lannett Company, Inc. These tablets must be stored at a controlled room temperature between 20°C to 25°C and protected from moisture. The recommended dosage and administration instructions are provided in accompanying literature. The product is made in France and comes in a bottle of 100 tablets with the NDC number 0527-1920-01. It is available on prescription only and should be kept out of reach of children.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
